Pharma
What 23andMe’s Regeneron sale means for the industry
This completes the company’s yearslong fall from its $6 billion peak.
This completes the company’s yearslong fall from its $6 billion peak.
A look at the earnings reported so far this year.
The decision came after sales plummeted amid competition from compounders and Eli Lilly.
The agency released draft guidance for the program that includes Part B drugs and price renegotiations.
Pharma companies love the news, but analysts express concern over how it may impact payers and hospitals.
Both drugmakers saw strong YoY sales, though Novo’s GLP-1 sales were down slightly from Q4 2024.
Healthcare Brew covers pharmaceutical developments, health startups, the latest tech, and how it impacts hospitals and providers to keep administrators and providers informed.